The European Medicines Agency is this week set to decide whether to recommend pan-EU marketing authorization for eight new products including teclistamab, Janssen Pharmaceutical’s investigational orphan drug for treating relapsed or refractory multiple myeloma (RRMM).
Teclistamab is an off-the-shelf, T-cell redirecting, bispecific antibody targeting both B-cell maturation antigen (BCMA) and CD3 that during its development...








